Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.
Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores
Ryo Sakamoto, Hiromichi Matsuoka, Emi Gomi, Akinori Kawaguchi, Shiho Takehisa and Atsuko Koyama
Background: The Anti-cholinergic drug Biperiden is used to treat Parkinsonism, Parkinsonism as an adverse effect of Psychotropic drugs, Dyskinesia, and Akathisia. In the palliative care field, Biperiden is used to treat Akathisia that has developed as an adverse effect of antipsychotics for managing delirium. There are tablets, granules, and injectable preparations of this drug; thus, it can be used for patients with various conditions.
Discussion: In addition to changing and withdrawing the causative drug, Propranolol, Mirtazapine, and Biperiden, an anticholinergic drug, may be administered to manage drug-induced Akathisia. However, Biperiden used to treat drug-induced Akathisia may exacerbate the Akathisia.
Conclusion: Here, we describe administering intramuscular Biperiden to a patient with gastric cancer at the end of life. When Biperiden is administered to treat drug-induced Akathisia and exacerbation of the Akathisia occurs, it is important to consider whether the deterioration in Akathisia is caused by the Biperiden, rather than simply continuing to administer it.